Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2016 - 20202

Settings

Author: search.filters.author.Buyukkurt, NurhilalSubject: search.filters.subject.chronic myeloid leukemia

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Second Malignancies İn Philadelphia-Positive and -Negative Myeloproliferative Neoplasms: A Single Center Study
    (2016) Solmaz, Soner; Korur, Asli; Gereklioglu, Cigdem; Asma, Suheyl; Buyukkurt, Nurhilal; Kasar, Mutlu; Yeral, Mahmut; Kozanoglu, Ilknur; Boga, Can; Ozdogu, Hakan; https://orcid.org/0000-0002-5086-5593; https://orcid.org/0000-0002-0895-4787; https://orcid.org/0000-0003-3856-7005; https://orcid.org/0000-0002-9580-628X; https://orcid.org/0000-0002-8902-1283; AAD-5616-2021; AAE-1457-2021; AAL-3906-2021; ABC-4148-2020; AAD-6222-2021; AAD-5542-2021
    Introduction: Leukemic transformation (LT) of both Philadelphia (Ph) -positive and -negative myeloprolifetarive neoplasms (MPNs) is a well-known subject. However sufficient data are not available in literature from Turkey about the frequency of second malignancies (SMs) except IT in patients with MPNs. In this study, it was aimed to investigate the frequency of SMs in Ph-positive or -negative MPN cases. Materials and Methods: A total of 438 patients diagnosed with classical MPN according to WHO 2008 diagnostic criteria were included in the study. Results: SMs were detected in 15 out of 438 patients (3.4%). In this study, cancer incidence rate was found higher (1149.8/100.000 person-years for males and 540.8/100.000 person-years for females with MPNs) compared with Turkey data. Conclusion: SM frequency is significantly higher than normal population in patients with MPNs. Therefore these patients should be carefully examined for SM symptoms and signs.
  • No Thumbnail Available
    Item
    Significance of Lymphocyte Count, Monocyte Count, and Lymphocyte-To-Monocyte Ratio in Predicting Molecular Response in Patients with Chronic Myeloid Leukemia: a Single-Centre Experience
    (2020) Pepedil-Tanrikulu, Funda; Buyukkurt, Nurhilal; Korur, Asli; Sariturk, Cagla; Aytan, Pelin; Boga, Can; Ozdogu, Hakan; Kozanoglu, Ilknur; 0000-0002-5268-1210; 0000-0002-0895-4787; 0000-0002-8902-1283; 0000-0002-5086-5593; 0000-0002-9680-1958; 32162884; AAE-1241-2021; AAD-6222-2021; AAE-1457-2021; AAD-5542-2021; AAD-5616-2021
    Background: Chronic myeloid leukemia (CML) is a disease resulting from BCR-ABL gene fusion. It is possible to monitor treatment by molecular testing for BCR-ABL. The lymphocyte-to-monocyte ratio (LMR) is a commonly used marker associated with prognosis in various neoplasms. This study was performed to evaluate the relevance of absolute lymphocyte count (ALC), absolute monocyte count (AMC), and LMR in predicting molecular response status in patients with chronic phase CML. Methods: Samples submitted to our hematology laboratory for BCR-ABL testing between April 2012 and October 2018 were retrospectively reviewed. Concurrent hemogram testing together with the results of quantitative reverse transcriptase-polymerase chain reaction were noted. Data were grouped according to molecular response status and the ALC, AMC, and LMR were compared among patient groups. Results: A total of 224 samples from 95 patients were included in the study. Analysis revealed differences between groups when newly diagnosed patients were compared with patients undergoing treatment, regardless of response status. However, analyzing the groups according to molecular response status failed to reveal differences in ALC, AMC, or LMR. Conclusions: ALC, AMC, and LMR are not potential biomarkers for predicting molecular response status in patients with chronic phase CML.